Home/Pipeline/BASH-004

BASH-004

Parkinson's Disease

PreclinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Preclinical

Status

Active

Company

Bash Biotech

About Bash Biotech

Bash Biotech is a private, preclinical-stage biotech based in San Francisco, applying a dual-platform approach of AI/ML and systems biology to decode host-microbiome interactions for therapeutic discovery. The company has a nascent pipeline targeting major unmet needs in chronic kidney disease, kidney cancer, Alzheimer's, and Parkinson's disease, all in preclinical development. Founded with $1M in seed funding, it is pre-revenue and focuses on building its proprietary data platforms (iNetModels, GutMicroNet) to drive its drug repositioning and target identification efforts.

View full company profile

Therapeutic Areas

Neurological Diseases Kidney Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active